CIK 0001566044 · Non-accelerated filer<br>Smaller reporting company
Yarrow Bioscience, Inc.
Sign in to watch- Ticker
- YARW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 453757789
- Phone
- (203) 433-7577
- Business address
- 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513
- Former names
- VYNE Therapeutics Inc., Menlo Therapeutics Inc., Menlo Therapeutics, Inc., Tigercat Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-01 | Stuart Iain Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2024-01-01 | Harsch Mutya Chief Legal Officer and GC | Grant or award | +62,500 | 149,596 | ||
| 2024-01-01 | Harsch Mutya Chief Legal Officer and GC | Grant or award · Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2024-01-01 | Domzalski David President and CEO | Grant or award | +225,000 | 496,168 | ||
| 2024-01-01 | Domzalski David President and CEO | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2024-01-01 | Sandoval Elisabeth Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-01-01 | LEPORE PATRICK G Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-01-01 | Bruno Anthony D Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-01-01 | Basta Steven L Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-01-01 | BARBARI SHARON Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-01-01 | Borowski Christine Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-12-13 | Zeronda Tyler Chief Financial Officer | Grant or award | +62,500 | 69,430 | ||
| 2023-12-13 | Zeronda Tyler Chief Financial Officer | Grant or award · Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2023-12-13 | Stuart Iain Chief Scientific Officer | Grant or award | +62,500 | 71,555 | ||
| 2023-12-13 | Stuart Iain Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2023-12-13 | Harsch Mutya Chief Legal Officer and GC | Grant or award | +62,500 | 87,096 | ||
| 2023-12-13 | Harsch Mutya Chief Legal Officer and GC | Grant or award · Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2023-12-13 | Domzalski David President and CEO | Grant or award | +225,000 | 271,168 | ||
| 2023-12-13 | Domzalski David President and CEO | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2023-12-13 | Sandoval Elisabeth Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 |
Page 5 of 6 · 113 trades